Delivering Practical Legal Solutions for Canadian Innovators and Investors
As one of Canada’s top business law firms, Blake, Cassels & Graydon LLP (Blakes) provides exceptional legal services to leading businesses in Canada and around the world.
Blakes has a long history of representing pioneers and leaders in the life sciences industry. The firm advises Canadian companies operating in the sector and international companies entering the Canadian market, expanding operations in Canada or conducting cross-border business activities.
Companies of all sizes look to Blakes for the full range of legal services to guide them through their products’ life cycles: from discovery, commercialization and product marketing to finance, mergers and acquisitions, IPOs and beyond.
The Blakes team is internationally recognized in the life sciences sector, and many of its lawyers have advanced degrees in life sciences and related technologies. The firm helps its clients achieve their business goals by combining this sector specialization with top-tier legal expertise and commercially focused advice.
Trusted Advisors to Growing Companies
From angel and seed rounds to later-stage investments, the Blakes Life Sciences team has extensive experience with private debt and equity financing. It works closely with clients to structure transactions that are best suited to each company’s stage of development and desired trajectory. This includes regularly assisting emerging companies and their investors across Canada.
The team’s recent experience with Alberta innovators includes advising Calgary-based Orpyx Medical Technologies,a leader in diabetic foot ulcer and amputation prevention, on its US$20-million financing by Perceptive Advisors.
Other representative deals include the C$12-million seed financing of Vancouver-based Incisive Genetics, a developer of innovative genetic therapies, and the licensing and acquisition of certain assets from Quebec-based Repare Therapeutics by DCx Biotherapeutics.
The Blakes team’s experience extends to representing leading Canadian investors such as adMare BioInnovations, which it advised on the C$20-million launch of emerging biopharmaceutical company FORUS Therapeutics.
Driving Results Across Borders
Offering extensive cross-border financing experience, Blakes regularly acts on financings involving major companies with operations in both Canada and the U.S. These transactions underscore both the scale of the team’s work and the breadth of its geographic reach. Notable examples include advising Abdera Therapeutics, a precision oncology company, on its US$110-million Series B financing; Alpha-9 Oncology, a clinical-stage company that develops targeted radiopharmaceuticals, on its US$175-million Series C financing; and AbCellera Biologics, a clinical-stage company that develops antibody medicines, on its US$556-million IPO.
Find Out How Blakes Can Help
Click here to learn more about its Life Sciences team and the full range of legal services it offers companies in the sector.
